Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Products under Development by Stage of Development | 8 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Products under Development by Therapy Area | 9 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Products under Development by Indication | 10 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Products under Development by Companies | 13 | 2 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Companies Involved in Therapeutics Development | 21 | 7 |
| Chrysalis Pharma SAS | 21 | 1 |
| Griffin Discoveries BV | 22 | 1 |
| Johnson &Johnson | 23 | 1 |
| OSE Immunotherapeutics | 24 | 1 |
| Palau Pharma, S.A. | 25 | 1 |
| Sensorion S.A. | 26 | 1 |
| Ziarco Pharma Ltd | 27 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Drug Profiles | 28 | 18 |
| GD-134 Drug Profile | 28 | 1 |
| GD-136 Drug Profile | 29 | 1 |
| GD-48 Drug Profile | 30 | 1 |
| JNJ-28307474 Drug Profile | 31 | 1 |
| JNJ-28610244 Drug Profile | 32 | 1 |
| JNJ-40279486 Drug Profile | 33 | 1 |
| SENS-218 Drug Profile | 34 | 2 |
| Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 36 | 1 |
| Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma Drug Profile | 37 | 1 |
| Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders Drug Profile | 38 | 1 |
| toreforant tartrate Drug Profile | 39 | 2 |
| tritoqualine Drug Profile | 41 | 1 |
| UR-63325 Drug Profile | 42 | 2 |
| ZPL-389 Drug Profile | 44 | 2 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Dormant Projects | 46 | 3 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Discontinued Products | 49 | 1 |
| Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Featured News &Press Releases | 50 | 10 |
| Sep 19, 2016: Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress | 50 | 1 |
| Sep 07, 2016: Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK | 50 | 1 |
| Sep 01, 2016: Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo | 51 | 1 |
| Jun 13, 2016: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients | 52 | 1 |
| May 16, 2016: Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 | 53 | 1 |
| May 12, 2016: Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting | 53 | 1 |
| Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting | 54 | 1 |
| Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389 | 55 | 1 |
| Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 | 55 | 1 |
| Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis | 56 | 1 |
| Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo | 57 | 1 |
| Jun 18, 2014: Ziarco Secures 1.7M Grant from UK s Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis | 58 | 1 |
| Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325 | 58 | 2 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |